Free Trial

Goldman Sachs Group Inc. Grows Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Vaxcyte logo with Medical background

Goldman Sachs Group Inc. lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 12.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 481,119 shares of the company's stock after buying an additional 52,005 shares during the quarter. Goldman Sachs Group Inc. owned about 0.44% of Vaxcyte worth $30,214,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Eventide Asset Management LLC lifted its stake in shares of Vaxcyte by 54.5% during the 4th quarter. Eventide Asset Management LLC now owns 607,206 shares of the company's stock worth $38,133,000 after buying an additional 214,206 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in shares of Vaxcyte by 12.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 267,594 shares of the company's stock worth $16,805,000 after buying an additional 29,462 shares during the last quarter. Vestal Point Capital LP bought a new position in Vaxcyte during the fourth quarter worth about $32,970,000. Capital Research Global Investors increased its holdings in Vaxcyte by 2.3% in the 4th quarter. Capital Research Global Investors now owns 3,440,107 shares of the company's stock valued at $216,039,000 after buying an additional 75,980 shares during the period. Finally, Campbell & CO Investment Adviser LLC increased its holdings in Vaxcyte by 3.3% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 27,219 shares of the company's stock valued at $1,709,000 after buying an additional 877 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.


Analyst Ratings Changes

Several equities analysts have commented on PCVX shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a report on Thursday. Needham & Company LLC reissued a "buy" rating and issued a $95.00 target price on shares of Vaxcyte in a report on Thursday, May 9th.

View Our Latest Research Report on PCVX

Insider Buying and Selling

In related news, CEO Grant Pickering sold 2,616 shares of Vaxcyte stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $72.06, for a total transaction of $188,508.96. Following the sale, the chief executive officer now directly owns 144,746 shares in the company, valued at approximately $10,430,396.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Grant Pickering sold 2,616 shares of Vaxcyte stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $72.06, for a total transaction of $188,508.96. Following the sale, the chief executive officer now directly owns 144,746 shares in the company, valued at approximately $10,430,396.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total transaction of $490,160.00. Following the sale, the chief financial officer now owns 95,679 shares in the company, valued at $5,862,252.33. The disclosure for this sale can be found here. Insiders have sold a total of 86,483 shares of company stock worth $5,917,483 in the last ninety days. Company insiders own 3.10% of the company's stock.

Vaxcyte Stock Performance

Shares of Vaxcyte stock traded up $2.18 during midday trading on Friday, hitting $74.94. 1,572,161 shares of the company traded hands, compared to its average volume of 456,894. The stock has a market cap of $8.15 billion, a price-to-earnings ratio of -17.51 and a beta of 0.97. The firm's fifty day moving average price is $68.17 and its 200-day moving average price is $67.35. Vaxcyte, Inc. has a 12 month low of $44.20 and a 12 month high of $82.04.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.28. Equities research analysts forecast that Vaxcyte, Inc. will post -3.96 earnings per share for the current year.

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Featured Articles

Institutional Ownership by Quarter for Vaxcyte (NASDAQ:PCVX)

Should you invest $1,000 in Vaxcyte right now?

Before you consider Vaxcyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.

While Vaxcyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines